Metastatic castrate-resistant prostate (CRPC) cancer

Clinical trials for Metastatic castrate-resistant prostate (CRPC) cancer explained in plain language.

Never miss a new study

Get alerted when new Metastatic castrate-resistant prostate (CRPC) cancer trials appear

Sign up with your email to follow new studies for Metastatic castrate-resistant prostate (CRPC) cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

Patient choice in prostate cancer: two pills, one preference

Disease control Completed

This trial asks men with advanced prostate cancer which of two oral medications they prefer: the experimental drug ODM-201 or the approved drug enzalutamide. Both work by blocking male hormones that fuel cancer growth. Participants will take each drug for a period and then answer…

Matched conditions: METASTATIC CASTRATE-RESISTANT PROSTATE (CRPC) CANCER

Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control

Last updated Aug 19, 2026 00:00 UTC

Metastatic castrate-resistant prostate (CRPC) cancer

Get alerted when new Metastatic castrate-resistant prostate (CRPC) cancer trials appear

Patient choice in prostate cancer: two pills, one preference